Navigation Links
Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
Date:6/4/2013

CHICAGO, June 4, 2013 /PRNewswire/ -- Ambit Biosciences Corporation (Nasdaq: AMBI) announced today that multiple presentations from the Phase 2 ACE study of quizartinib (AC220), a FLT3 inhibitor, were presented at the Annual Meeting of the American Society of Clinical Oncology.

Data presented included analyses of the 333 patients with relapsed or refractory acute myeloid leukemia (AML) from a Phase 2 clinical trial of quizartinib as monotherapy. In the study, quizartinib was administered orally, once-a-day, in 28-day treatment cycles until disease progression, elective hematopoietic stem cell transplantation (HSCT) or unacceptable toxicity. Based on the positive data from the Phase 2 clinical trial, as well as ongoing discussions with the Food and Drug Administration (FDA), Ambit is planning to initiate a Phase 3 clinical trial in FLT3-ITD positive patients with relapsed or refractory AML in early 2014.

Data Presentations

High Response Rate and Bridging to Hematopoietic Stem Cell Transplantation with Quizartinib (AC220) in Patients with FLT3‑ITD Positive or Negative Relapsed/Refractory AML after Second Line Chemotherapy or Previous Bone Marrow Transplant (Abstract #7012)
Jorge Cortes , M.D., Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

Data from 176 patients, aged 18 years or older, with either relapsed disease or who were refractory to second-line chemotherapy or HSCT were presented. Of the 136 FLT3 positive patients, 35 percent were successfully bridged to a potentially curative HSCT, with the greatest proportion receiving a HSCT after achieving a CRi (complete remission with incomplete hematologic recovery) with quizartinib. Additionally, 33 percent of patients who were bridged to HCST afte
'/>"/>

SOURCE Ambit Biosciences Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
2. APAC Stem Cell Research & Therapy Market a “Growth Engine” for Region’s Scientific Ambitions Says A New Market Research Report at ReportsnReports.com
3. Astellas and Ambit Announce Data Presentations Highlighting Quizartinib at the American Society of Hematology 54th Annual Meeting
4. Ambit Biosciences to Present at Two Upcoming Investor Conferences
5. Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
6. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
7. Arteriocyte announces Launch of Compass Biomedical
8. TNI BioTech, Inc. Announces Death of Senior Vice President and Chief Medical Officer, Dr. Ronald Herberman
9. Elsevier Announces its Collaboration with Kasetsart University, Thailand
10. Celsion Corporation Announces $9.83 Million Registered Direct Offering
11. Caris Life Sciences Announces Planned Expansion of Next-Generation Sequencing (NGS) Capabilities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Davis, California (PRWEB) January 22, 2015 ... of Accelerator Mass Spectrometry (AMS) services to the pharmaceutical ... PhD has joined the company in the position of ... 30 years of broad and valuable experience in drug ...
(Date:1/22/2015)... RBJ today announces the firm brokered a long-term lease totaling ... biopharmaceutical company, at Two Ledgemont Center in Lexington, ... president, and Brian Cohen , senior vice president, represented ... 95 Hayden Ave. Photo - http://photos.prnewswire.com/prnh/20150122/170765 ...
(Date:1/22/2015)... RBJ today announces the firm brokered a long-term lease totaling ... biopharmaceutical company, at Two Ledgemont Center in Lexington, ... president, and Brian Cohen , senior vice president, represented ... 95 Hayden Ave. Photo - http://photos.prnewswire.com/prnh/20150122/170765 ...
(Date:1/22/2015)... The laboratory information management systems market ... number of technological advancements due to factors such as ... to integrate healthcare systems, and increasing government support for ... integration. Key players in the market focus on technological ...
Breaking Biology Technology:Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 2Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 3Transwestern | RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Transwestern?RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 3Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 4
... quarter of 2008 versus third quarter ... ... CRY ),a biomaterials, medical device and tissue processing company, announced,today that revenues ... to $22.2 million in the third quarter of 2007.,Excluding orthopaedic tissue processing ...
... Oct. 30 Human Genome,Sciences, Inc. (Nasdaq: HGSI ... to discuss its financial results for the quarter ended,September ... on Thursday,November 6, 2008, after the capital markets close., ... call will be hosted by senior management and will ...
... Pharmaceuticals,Inc. (Nasdaq: VNDA ), a biopharmaceutical company ... candidates for central,nervous system disorders, today announced financial ... 30, 2008., Vanda reported research and development ... $3.8 million, compared to $5.5 million in the ...
Cached Biology Technology:CryoLife's Fully Diluted Earnings Per Share Increased 71 Percent to $0.12 in Third quarter of 2008 from $0.07 in Third quarter of 2007 2CryoLife's Fully Diluted Earnings Per Share Increased 71 Percent to $0.12 in Third quarter of 2008 from $0.07 in Third quarter of 2007 3CryoLife's Fully Diluted Earnings Per Share Increased 71 Percent to $0.12 in Third quarter of 2008 from $0.07 in Third quarter of 2007 4CryoLife's Fully Diluted Earnings Per Share Increased 71 Percent to $0.12 in Third quarter of 2008 from $0.07 in Third quarter of 2007 5CryoLife's Fully Diluted Earnings Per Share Increased 71 Percent to $0.12 in Third quarter of 2008 from $0.07 in Third quarter of 2007 6CryoLife's Fully Diluted Earnings Per Share Increased 71 Percent to $0.12 in Third quarter of 2008 from $0.07 in Third quarter of 2007 7CryoLife's Fully Diluted Earnings Per Share Increased 71 Percent to $0.12 in Third quarter of 2008 from $0.07 in Third quarter of 2007 8CryoLife's Fully Diluted Earnings Per Share Increased 71 Percent to $0.12 in Third quarter of 2008 from $0.07 in Third quarter of 2007 9CryoLife's Fully Diluted Earnings Per Share Increased 71 Percent to $0.12 in Third quarter of 2008 from $0.07 in Third quarter of 2007 10CryoLife's Fully Diluted Earnings Per Share Increased 71 Percent to $0.12 in Third quarter of 2008 from $0.07 in Third quarter of 2007 11Human Genome Sciences to Sponsor Conference Call to Discuss Third Quarter 2008 Financial Results 2Vanda Pharmaceuticals Reports Third Quarter 2008 Results 2Vanda Pharmaceuticals Reports Third Quarter 2008 Results 3Vanda Pharmaceuticals Reports Third Quarter 2008 Results 4Vanda Pharmaceuticals Reports Third Quarter 2008 Results 5Vanda Pharmaceuticals Reports Third Quarter 2008 Results 6Vanda Pharmaceuticals Reports Third Quarter 2008 Results 7Vanda Pharmaceuticals Reports Third Quarter 2008 Results 8Vanda Pharmaceuticals Reports Third Quarter 2008 Results 9Vanda Pharmaceuticals Reports Third Quarter 2008 Results 10
(Date:12/17/2014)... Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) has announced the ... report to their offering. ... in this market is the increasing demand for medical ... of patient data for quick and correct diagnosis during ...
(Date:12/11/2014)... and Markets , http://photos.prnewswire.com/prnh/20130307/600769 ... the addition of the "Biometrics Market in India ... One major trend emerging in this market is the ... more than one characteristic of an individual for verification ...
(Date:12/10/2014)... , Dec. 9, 2014  Valencell, a leader in performance ... a staggering demand from its licensees for highly accurate, ... is not solely coming from fitness and health sectors, ... "A wearable is only as useful as the ...
Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... is easy: we call it fire. But ... oxygen to a particular carbon atom in a complicated ... to an enzyme called cytochrome P450. Because cytochrome P450 ... been called "nature,s blowtorch," and its job is analogous ...
... issue of GEOSPHERE, published by the Geological Society ... interest include common ground in the disagreement between ... a USGS Great Basin Paleontological Database filled with ... terrestrial laser scanners and digital cameras in three-dimensional ...
... (EMBL) in Heidelberg, Germany, and the EMBL-European Bioinformatics Institute ... how sex chromosomes are regulated. A chromatin modifying enzyme ... one copy of the sex chromosome X, while females ... sex chromosomes in fruit flies and binds to different ...
Cached Biology News:A molecular switch turns on the flame in 'nature's blowtorch' 2June GEOSPHERE media highlights 2June GEOSPHERE media highlights 3June GEOSPHERE media highlights 4X chromosome exposed 2
... sensitive laser confocal systems designed for rapid ... that meet your expectations, differentiating between a ... the signal on the bottom as well ... for increased sensitivity. Results with VersArray ChipReader ...
... one plate. The new ArraySlide 96 chamber ... x 7mm) individual printing surfaces for multiple ... studies. Unlike other systems, this device utilizes ... of contaminating adhesives. The chamber itself is ...
Bio-Plex Manager software, version 3.0, 5 license netshare, is a five-user software package that provides access to data from the Bio-Plex suspension array system from a server. This version does not...
... Hyb-Seal slide chambers are vapor-tight adhesive chambers for ... chambers are affixed over a sample on a ... of two ports, and the ports are then ... removed and replaced to allow exchange of reaction ...
Biology Products: